BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turku A, Rinne MK, Boije Af Gennäs G, Xhaard H, Lindholm D, Kukkonen JP. Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity. PLoS One 2017;12:e0178526. [PMID: 28575023 DOI: 10.1371/journal.pone.0178526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Calva CB, Fadel JR. Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction. Brain Res 2020;1731:145921. [PMID: 30148983 DOI: 10.1016/j.brainres.2018.08.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
2 Karhu L, Magarkar A, Bunker A, Xhaard H. Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study. J Phys Chem B 2019;123:2609-22. [PMID: 30786708 DOI: 10.1021/acs.jpcb.8b10220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Calva CB, Fayyaz H, Fadel JR. Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats. Front Aging Neurosci 2019;11:362. [PMID: 32038222 DOI: 10.3389/fnagi.2019.00362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhang D, Perrey DA, Decker AM, Langston TL, Mavanji V, Harris DL, Kotz CM, Zhang Y. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. J Med Chem 2021;64:8806-25. [PMID: 34101446 DOI: 10.1021/acs.jmedchem.1c00841] [Reference Citation Analysis]
5 Turku A, Leino TO, Karhu L, Yli-Kauhaluoma J, Kukkonen JP, Wallén EAA, Xhaard H. Structure-Activity Relationships of 1-Benzoylazulenes at the OX1 and OX2 Orexin Receptors. ChemMedChem 2019;14:965-81. [PMID: 30892823 DOI: 10.1002/cmdc.201900074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
7 Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Front Endocrinol (Lausanne) 2018;9:573. [PMID: 30319552 DOI: 10.3389/fendo.2018.00573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Janockova J, Dolezal R, Nepovimova E, Kobrlova T, Benkova M, Kuca K, Konecny J, Mezeiova E, Melikova M, Hepnarova V, Ring A, Soukup O, Korabecny J. Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods. Molecules 2018;23:E2926. [PMID: 30423961 DOI: 10.3390/molecules23112926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Varela R, Rauschert I, Romanelli G, Alberro A, Benech JC. Hyperglycemia and hyperlipidemia can induce morphophysiological changes in rat cardiac cell line. Biochem Biophys Rep 2021;26:100983. [PMID: 33912691 DOI: 10.1016/j.bbrep.2021.100983] [Reference Citation Analysis]
10 Calva CB, Fayyaz H, Fadel JR. Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1). J Neurochem 2018;145:232-44. [PMID: 29250792 DOI: 10.1111/jnc.14279] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
11 Rinne MK, Leino TO, Turku A, Turunen PM, Steynen Y, Xhaard H, Wallén EA, Kukkonen JP. Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26. European Journal of Pharmacology 2018;837:137-44. [DOI: 10.1016/j.ejphar.2018.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
12 Leino TO, Turku A, Yli-kauhaluoma J, Kukkonen JP, Xhaard H, Wallén EA. Azulene-based compounds for targeting orexin receptors. European Journal of Medicinal Chemistry 2018;157:88-100. [DOI: 10.1016/j.ejmech.2018.07.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Karhu L, Weisell J, Turunen PM, Leino TO, Pätsi H, Xhaard H, Kukkonen JP, Wallén EAA. Stapled truncated orexin peptides as orexin receptor agonists. Peptides 2018;102:54-60. [PMID: 29475074 DOI: 10.1016/j.peptides.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Gupta R, Sharma D. Manganese-Doped Magnetic Nanoclusters for Hyperthermia and Photothermal Glioblastoma Therapy. ACS Appl Nano Mater 2020;3:2026-37. [DOI: 10.1021/acsanm.0c00121] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]